Kuros Biosciences (KURN) CMD 2025 summary

Strategic Focus and Business Transformation

• Shifted to a pure medtech strategy in late 2023, discontinuing non-core assets to focus on MagnetOs, a synthetic bone graft with strong clinical evidence and high growth potential.

• Achieved rapid revenue growth, reaching CHF 75.6 million in 2024, with guidance to CHF 220–250 million by 2027, and targeting CHF 100 million in half the originally planned time.

• Expanded global footprint, now present in over 25 countries, with significant growth in the U.S., Europe, and strategic entry into Brazil, New Zealand, UAE, and other international markets.

• Built a scalable, digitized operational backbone, including new ERP systems, automation, and dual production sites in the Netherlands and the U.S. to support volume and de-risk supply chain.

• Maintains profitability and no debt, investing operational cash flow into growth, R&D, and selective M&A aligned with a science-first ethos.

Product Innovation and Clinical Evidence

• MagnetOs leverages proprietary NeedleGrip surface technology, achieving superior fusion rates to autograft in Level I clinical studies, including 79% vs. 47% overall and 74% vs. 30% in smokers.

• Multiple MagnetOs formulations (Granules, Putty, Easypack Putty, Flex Matrix, MIS) address diverse surgical needs and are cleared for use in spine, extremities, and pelvis.

• Seven Level I clinical studies ongoing, with over 35 studies in total, supporting claims in spine, extremities, trauma, oncology, and potential osteoporosis applications.

• Ongoing robust R&D pipeline, including adaptation of surface technology to metals and new biomaterial applications, with a focus on evidence-based expansion.

• MagnetOs minimizes safety concerns by containing no human cells or growth factors and offers broad indications with predictable handling.

Commercial Expansion and Market Opportunities

• U.S. remains the primary revenue driver (95%), with plans to grow international share to 10–15% via distributor models and strategic partnerships.

• Medtronic alliance provides access to tier-one salesforce and accelerates U.S. market penetration, while maintaining control over revenue and brand.

• Entered the $1 billion extremities market, leveraging spine clinical data and KOL engagement to build presence in foot, ankle, and trauma segments.

• Scalable sales model and increased distributor network (from 91 to 150 in 2024) support global growth and operational efficiency.

• Pricing strategy leverages clinical evidence to maintain or increase ASP, especially for new, user-friendly product formats.